Leslie A. Fecher
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab (NIVO) significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab (IPI) in patients with resected stage IIIB–C or stage IV melanoma, with benefit sustained at 4 years. We report updated 5-year efficacy and biomarker findings. Patients and Methods: Patients with resected stage IIIB–C/IV melanoma were stratified by stage and baseline PD-L1 expression and received NIVO 3 mg/kg every 2 weeks or IPI 10 mg/kg every 3 weeks for four doses and then every 12 weeks, both intravenously for 1 year until disease recurrence, unacceptable toxicity, or withdrawal of consent. The primary endpoint was RFS. Results: At a minimum follow-up of 62 months, RFS with NIVO remained superior to IPI (HR 0.72; 95% CI, 0.60–0.86; 5-year rates of 50% versus 39%). 5-year DMFS rates were 58% with NIVO versus 51% with IPI. Five-year OS rates were 76% with NIVO and 72% with IPI (75% data maturity: 228 of 302 planned events). Higher levels of TMB, tumor PD-L1, intratumoral CD8+ T cells and interferon-gamma–associated gene expression signature, and lower levels of peripheral serum C-reactive protein were associated with improved RFS and OS with both NIVO and IPI, albeit with limited clinically meaningful predictive value. Conclusion: NIVO is a proven adjuvant treatment for resected melanoma at high-risk of recurrence, with sustained, long-term improvement in RFS and DMFS compared with IPI and high OS rates. Identification of additional biomarkers are needed to better predict treatment outcome.
Year:
2024
The overall survival of advanced melanoma has improved dramatically. Immunotherapies, specifically checkpoint inhibitors, have played a large role in this improvement. These agents have also shown benefit in the adjuvant setting, are approved for treatment of resected stage II, III, and IV melanoma, and play an evolving role in the neoadjuvant setting. Although generally well tolerated, immune-related adverse events occur and can be severe. Here we focus on some severe and potentially long term toxicities, including cardiovascular and neurologic toxicities. Our understanding of the acute and long-term toxicities of immune checkpoint inhibitors continues to evolve. Oncologists must continue to balance cancer risk and treatment-related toxicities.
Year:
2023
Collaborators (12)
vanna chiarion sileni
Chief of Melanoma Oncology Unit
-
James Larkin
Professor
-
Ana Arance
University of Barcelona
Nikhil Khushalani
Assistant Center Director for Clinical Research Review and Partnerships; Senior Member and Vice-Chair, Department of Cutaneous Oncology
H Lee Moffitt Cancer Center and Research Institute
Marcus Butler
University Health Network
Jean-Jacques Grob
Aix-Marseille University
Helen Gogas
Head, Professor in Medical Oncology
National and Kapodistrian University of Athens
Paul Nathan
University College London
Ivan Marquez-Rodas
Universidad Complutense de Madrid
Mark Middleton
University of Oxford
Paolo Antonio Ascierto
Full Professor
Università degli Studi di Napoli Federico II
Mario Mandalà
Associate Professor
University of Perugia
Make your next move.
Prepare your application
Review drafts before you send them.